Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has signed a project agreement with Zhejiang University for the development and industrialization of bio-synthesized anticoagulant heparin, with a total project amount of 120 million yuan, aiming to provide green innovative solutions for the global anticoagulant drug market [1][3]. Group 1: Market Context - The domestic heparin market has nearly reached 30 billion yuan, while the global market has surpassed 10 billion USD [3]. - The demand for heparin drugs is increasing due to factors such as an aging population, rising surgical procedures, and increasing chronic disease prevalence [3]. Group 2: Challenges in Traditional Production - Traditional heparin production relies on pig intestinal mucosa, leading to supply instability, quality fluctuations, and environmental pressures [3]. - The bio-synthesis method using microbial fermentation technology offers a sustainable supply of raw materials and significantly improves quality control [3]. Group 3: Company Expertise and Strategy - Haizheng Pharmaceutical has 69 years of experience in the pharmaceutical field and over 55 years of expertise in microbial technology [3]. - The collaboration will enhance Haizheng's product matrix in the anticoagulant drug sector, optimize existing industrial resources, and improve competitiveness in the high-end biopharmaceutical market [3][4]. Group 4: Project Significance - The bio-engineered heparin project is a core initiative of the research institute, marking a significant transition from laboratory research to industrial application [4]. - The partnership aims to disrupt traditional animal extraction methods for heparin production, facilitating a comprehensive process from laboratory research to mass production [4]. Group 5: Future Aspirations - The collaboration seeks to establish a globally leading research and production platform for anticoagulant drugs, filling the clinical application gap for bio-engineered heparin and providing safer and more effective treatment options for patients worldwide [5].